Literature DB >> 9437483

Nosocomial infections in an oncology intensive care unit.

E Velasco1, L C Thuler, C A Martins, L M Dias, V M Gonçalves.   

Abstract

INTRODUCTION: Treatment of cancer has contributed to a growing number of immunocompromised patients with life-threatening nosocomial infections (NI). High mortality with considerable cost is observed when they are admitted to the intensive care unit (ICU). Few studies on infection control and surveillance have been undertaken in this population group.
METHODS: All patients treated at a six-bed medical-surgical oncology ICU for > 48 hours were prospectively observed for the development of an NI and the influence of device utilization on infection rates. The analysis used the standard definitions of the National Nosocomial Infection Surveillance System Intensive Care Unit surveillance component.
RESULTS: From September 1993 through November 1995, 370 infections occurred in 623 patients during 4034 patient-days, for an overall rate of 50.0 per 100 patients or 91.7 per 1000 patient-days. Pneumonia (28.9%), urinary tract infections (25.6%), and bloodstream infections (24.1%) were the main types of infection. The most common microorganisms isolated were Enterobacteriaceae (29.7%), fungi (22.2%), and Pseudomonas aeruginosa (13.2%). The median device utilization ratios were 0.63, 0.83, and 0.86 for ventilator, indwelling urinary catheter, and central venous catheter, respectively. The highest median device-specific associated infection rate was 41.7 for ventilator. The median for the average length of stay was 8.8 days, and the average severity of illness score was 4.0. There was a strong positive correlation between the overall NI patient rate and device utilization (r = 0.56, p < 0.01), average severity of illness score (r = 0.54, p < 0.01), and average length of stay (r = 0.67, p < 0.01). No correlations were statistically significant when patient-days were used in the denominator. Among the devices only the number of central venous catheter days was significantly correlated with infections (r = 0.51, p = 0.01). The NI patient-day rates were progressively higher the longer the patients stayed in the ICU.
CONCLUSIONS: The high rates reported in this study may reflect a combination of several factors related to the underlying illness, neutrophil count, and exposure to invasive procedures. The adjusted infection rates described here provide specific surveillance data for further interhospital comparisons and also to assess the influence of invasive medical interventions, allowing the implementation of preventable measures to control infections.

Entities:  

Mesh:

Year:  1997        PMID: 9437483     DOI: 10.1016/s0196-6553(97)90067-5

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  12 in total

1.  ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa.

Authors:  Arne Rietsch; Isabelle Vallet-Gely; Simon L Dove; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

2.  Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study.

Authors:  Youssef A Al-Tonbary; Othman E Soliman; Mohammed M Sarhan; Moustafa A Hegazi; Rasha A El-Ashry; Ashraf A El-Sharkawy; Osama S Salama; Raida Yahya
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

3.  Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo.

Authors:  Russell E Vance; Arne Rietsch; John J Mekalanos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Metabolic regulation of type III secretion gene expression in Pseudomonas aeruginosa.

Authors:  Arne Rietsch; John J Mekalanos
Journal:  Mol Microbiol       Date:  2006-02       Impact factor: 3.501

5.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols.

Authors:  Manju Panghal; Vivek Kaushal; Sangeeta Kadayan; Jaya Parkash Yadav
Journal:  BMC Oral Health       Date:  2012-07-20       Impact factor: 2.757

7.  Nosocomial Infections among Pediatric Patients with Neoplastic Diseases.

Authors:  Peninnah Oberdorfer; Natthida Pongwilairat; Charles H Washington
Journal:  Int J Pediatr       Date:  2009-10-26

8.  Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004-2010: a surveillance-based study.

Authors:  Catherine Huoi; Philippe Vanhems; Marie-Christine Nicolle; Mauricette Michallet; Thomas Bénet
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  Characteristics and outcomes of cancer patients in European ICUs.

Authors:  Fabio Silvio Taccone; Antonio A Artigas; Charles L Sprung; Rui Moreno; Yasser Sakr; Jean-Louis Vincent
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

10.  Diversity of Bacterial Communities on Four Frequently Used Surfaces in a Large Brazilian Teaching Hospital.

Authors:  Tairacan Augusto Pereira da Fonseca; Rodrigo Pessôa; Alvina Clara Felix; Sabri Saeed Sanabani
Journal:  Int J Environ Res Public Health       Date:  2016-01-22       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.